Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium-Reference-Cited by-同舟云学术

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Published:2021-06 Issue: Volume:150 Page:53-62
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pasqualini Claudia^ORCID,Rubino Jonathan^ORCID,Brard Caroline^ORCID,Cassard Lydie^ORCID,André Nicolas,Rondof Windy,Scoazec Jean-Yves^ORCID,Marchais Antonin,Nebchi Souad,Boselli Lisa^ORCID,Grivel Jonathan,Aerts Isabelle,Thebaud Estelle,Paoletti Xavier,Minard-Colin Véronique,Vassal Gilles,Geoerger Birgit

Funder

INCa

Fondation ARC pour la Recherche sur Le Cancer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries;Grabow;Eur J Epidemiol,2018

2. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity;Topalian;Curr Opin Immunol,2012

3. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

4. Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges;Giroux Leprieur;Eur J Canc,2017

5. Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma: a review;George;JAMA Oncol,2019

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART;European Journal of Cancer;2024-09

2. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08

3. Metronomic chemotherapy in pediatric neurooncology: insight the problem. A review;Journal of Modern Oncology;2024-07-03

4. Differential RNA Expression Between Metastatic and Primary Neuroblastoma Cells;Journal of Surgical Research;2024-06

5. The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapies;EJC Paediatric Oncology;2024-06